Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(9 sites)

United States

Mount Sinai Hosp Med School, New York, New York

France

Novartis Investigative Site, Paris

Novartis Investigative Site, Vandœuvre-lès-Nancy

Germany

Novartis Investigative Site, Essen

Novartis Investigative Site, München

Italy

Novartis Investigative Site, Milan

Novartis Investigative Site, Naples

Spain

Novartis Investigative Site, Granada, Andalusia

Novartis Investigative Site, El Palmar, Murcia